Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01961323 · ClinicalTrials.gov registry record · Phase 4

Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart

A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
Phase 4
Development phase
70
Enrollment target

NCT01961323 is a Phase 4 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 70 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01961323, a Phase 4 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
Phase 4
Development phase
70 participants
Enrollment target

Study Summary

To investigate whether treatment with Nebivolol in subjects with high blood pressure and abnormal filling of left ventricle (LVDD) improves exercise time by improving Left Ventricular deformation and filling.

Interventions

  • DRUG Nebivolol

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2012-03
Est. Completion 2016-03
Phase Phase 4

What the Registry Record Tells You About NCT01961323

The ClinicalTrials.gov registry entry for NCT01961323 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Nebivolol is the first listed.

NCT01961323 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01961323 about?

NCT01961323 is a clinical study titled "Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart". To investigate whether treatment with Nebivolol in subjects with high blood pressure and abnormal filling of left ventricle (LVDD) improves exercise time by improving Left Ventricular deformation and filling.

What is the current status of trial NCT01961323?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2012-03. Estimated completion is 2016-03.

What interventions are being tested in trial NCT01961323?

The interventions under investigation include: Nebivolol (DRUG).

Who is sponsoring clinical trial NCT01961323?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.